Ovarian Cancer Diagnostic Market - By Product Type (Instruments/Analyzers, Consumables), Diagnostic Tests (Imaging [CT, MRI, Ultrasound], Blood Test, Biopsy), Cancer Type (Epithelial, Germ Cell, Stromal Cell Tumor), End-use – Global Forecast 2024 – 2032

North America ovarian cancer diagnostic industry accounted for USD 624.4 million in 2023 and is predicted to witness substantial growth through 2032, driven by an advanced healthcare infrastructure and high levels of awareness regarding the importance of early cancer detection.

Abbott Laboratories, Agilent Technologies, Canon Medical Systems Corporation, Danaher Corporation, F. Hoffmann-La Roche Ltd., Fujirebio Diagnostics, GE HealthCare Technologies Inc., Illumina Inc., Myriad Genetics, Philips Healthcare, Positron Corporation are some of the major industry contenders.

Global ovarian cancer diagnostic industry was valued at around USD 1.54 billion in 2023 and is estimated to reach over USD 2.71 billion by 2032, driven by increasing incidences of ovarian cancer worldwide.

Instruments/analyzers segment garnered USD 965.7 million in 2023 and is set to gain traction by 2032, driven by technological advancements and growing awareness about the importance of early detection and screening for ovarian cancer.